Basius77 / Shutterstock.com Quick Read PepsiCo generated $18.8B in operating cash flow in 2024 and maintains 52+ years of consecutive dividend increases. Chevron’s 95% payout ratio from earnings signals risk despite strong 2.67x cash flow coverage. AbbVie’s 501% earnings payout ratio is offset by 58.6% cash flow payout from $18.8B operating cash flow. If you’re thinking about retiring or know someone who is, there are three quick questions causing many Americans to realize they can retire earlier ...

Core Insights - BioNTech and Bristol Myers Squibb announced promising interim data from a Phase 2 trial evaluating pumitamig, a bispecific antibody targeting PD-L1 and VEGF-A, in combination with chemotherapy for treating locally advanced/metastatic triple-negative breast cancer (TNBC) [1][2][6] Efficacy - The combination of pumitamig and chemotherapy achieved a confirmed objective response rate (cORR) of 61.5%, an unconfirmed objective response rate (uORR) of 71.8%, and a disease control rate (DCR) of 92.3%, regardless of PD-L1 expression levels [6][7] - Efficacy was consistent across different dose levels and treatment lines, with higher doses correlating with better responses: uORR was 63.2% at 15 mg/kg and 80.0% at 20 mg/kg [7] - The progression-free survival (PFS) rate at 9 months was reported at 59.3%, although median PFS and overall survival (OS) data were not mature at the time of analysis [7] Safety - Pumitamig demonstrated a manageable safety profile, with grade ≥3 treatment-related adverse events (TRAEs) reported in 42.5% of patients in Cohort 1 and 38.2% in Cohort 2, with no deaths attributed to pumitamig [7][8] Clinical Trial Details - The trial evaluated two dose levels of pumitamig in combination with four different chemotherapy agents for first- and second-line treatment of TNBC [3][9] - The ongoing Phase 3 trial, ROSETTA BREAST-01, will further investigate pumitamig plus chemotherapy versus placebo plus chemotherapy in patients with PD-L1 negative TNBC [8][12] Industry Context - Triple-negative breast cancer (TNBC) accounts for 10-15% of all invasive breast cancer cases and has a poor prognosis, with a 5-year survival rate of only 15% in advanced stages, highlighting the urgent need for new treatment options [3][10] - Current standard care for PD-L1 low or negative TNBC is chemotherapy alone, as existing PD-(L)1 inhibitors have shown limited efficacy in this subgroup [10][11]

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASH--Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025. ...

Key Takeaways Bristol Myers Squibb will continue the phase III ADEPT-2 study on Cobenfy in Alzheimer's psychosis.The study's readout shifts to next year following data review and a committee recommendation.Cobenfy's early schizophrenia sales hit $105M as it targets broader indications across Alzheimer's programs.Bristol Myers Squibb (BMY) recently announced that it will continue the phase III ADEPT-2 study on Cobenfy in psychosis associated with Alzheimer's disease.The decision to continue the study follows ...

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best US Stocks to Buy for Long Term. Leerink Maintains Outperform Rating as Bristol Myers (BMY) Expands ADEPT-2 Enrollment On December 4, Leerink analyst David Risinger maintained an Outperform rating on Bristol-Myers Squibb Company (NYSE:BMY). The analyst highlighted that the company plans to enroll more patients in the ADEPT-2 study and sees this as a positive development. He noted that the Data Monitoring Committee also suggested expandi ...

China has approved 19 innovative medicines — including major treatments from Eli Lilly, Pfizer, and Johnson & Johnson — for its first commercial health insurance drug catalog, creating a new pathway for companies to sell advanced therapies at better prices.The announcement was made Sunday in Guangzhou, marking a major shift in how China plans to support costly drugs that are too expensive for its state insurance program.The new list includes medicines for cancer, Alzheimer's disease, and rare genetic condit ...

（文章来源：每日经济新闻） "2025创新药高质量发展大会"今天（12月7日）上午在广州召开，会议将发布2025年《国家基本医疗保 险、生育保险和工伤保险药品目录》和首版《商业健康保险创新药品目录》。 复星凯瑞董事长张文杰表示，创新药的质量不仅来自药品本身，还来自患者可及性。商保谈判机制是中 国创新药可及性的一个极其重要的里程碑。 据大会现场公布，百时美施贵宝、卫材、武田制药、礼来、复星凯瑞、北海康成等多家企业新药产品入 围首版《商业健康保险创新药品目录》。首版商保创新药目录共纳入19种药品，5款百万元级别的CAR- T肿瘤疗法全部纳入，社会关注度较高的阿尔茨海默病治疗药品、罕见病药物等也被纳入其中。 ...

Austin, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Peptide Therapeutics Market Size & Growth Analysis: According to SNS Insider, the Peptide Therapeutics Market size was valued at USD 46.04 billion in 2024 and is expected to reach USD 82.19 billion by 2032, growing at a CAGR of 7.51% over 2025-2032. The demand for targeted, customized, and specialized medications in oncology, metabolic disease, and infectious disease is driving the growth of the worldwide peptide therapeutics market. The U.S. peptide therapeutics ma ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it might be a comeback to the drug stocks. Why? Well, remember, lots of people think the economy is stalled or in a tailspin. They’re wrong, but they’ll want to participate. When money managers are worried about the economy, they reach for Johnson & Johnson, Merck, Eli Lilly, Vertex… and Amgen, and even lowly worm Bris ...

These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?The pharmaceutical industry is highly competitive, and currently, the leading company in the sector is likely Eli Lilly (LLY 0.41%). That's driven by the fact that Eli Lilly makes the weight loss drugs Zepbound and Mounjaro, which together account for over 50% of the company's revenue. That's an interesting statistic because it highlights both the risk and opportunity that exists in the drug sector.If you own o ...